Introduction {#s1}
============

Extended-spectrum beta-lactamases (ESBLs) are mainly plasmid-encoded enzymes providing resistance to 3rd generation (3G) cephalosporins. These enzymes can be produced by a variety of different bacteria, such as *Enterobacteriaceae* or non-fermenting bacteria (Bradford, [@B6]; Giamarellou, [@B15]; Rawat and Nair, [@B26]; Shaikh et al., [@B28]). The most frequently found ESBL-producing species is *Escherichia coli* which often causes urinary tract infections, pneumonia or even sepsis in humans (Abraham et al., [@B3]). ESBL-producing *E. coli* has been broadly recognized in veterinary medicine as causative agents of mastitis in dairy cattle since the 2000s (Brinas et al., [@B8]; Haftu et al., [@B16]), but only a few studies exist that investigated the prevalence of ESBL-producing bacteria in livestock, showing their existence in sick and/or healthy cattle (Valentin et al., [@B30]; Dahms et al., [@B12]).

Unfortunately, there is no legislation in Egypt regulating the use of antibiotics (Dahshan et al., [@B13]). Antimicrobials such as tetracycline, quinolones, and beta lactams are still used in Egypt for growth promotion in animal feed and by veterinarians for the treatment and prevention of zoonotic diseases (WHO, [@B31]).

The CTX-M beta-lactamases, named for their greater activity against cefotaxime, are the most frequently detected ESBLs in livestock, and have been reported from different food-producing animals (Schmid et al., [@B27]; Brolund, [@B9]; Hansen et al., [@B17]). These animals also represent a source and/or a reservoir for ESBL-producing *E. coli* (Carattoli, [@B10]). Several studies indicate that these resistance genes are disseminated through the food chain or via direct contact between humans and animals (Schmid et al., [@B27]; Dahms et al., [@B12]). Data on ESBL-producing bacteria in food animals from Egypt are very limited. Therefore, the current study was conducted on four dairy cattle farms in different districts of Northern Egypt to assess the prevalence of ESBL-producing *E. coli* in dairy cattle and their environment.

Materials and methods {#s2}
=====================

Farm description and sampling
-----------------------------

In 2014, four dairy farms, three in Gamasa (GF1, GF2, GF5), and one in Damietta (D), were investigated (Figure [1](#F1){ref-type="fig"}). These farms were located in Nile Delta, Egypt in two different governorates (Damietta; Latitude N. 31⋅19′, Longitude E. 31⋅81′ and Dakahlia Latitude N. 31⋅25′, Longitude E. 31⋅32′). The herd size ranged from 400, 600, 650, and 800 in GF1, GF2, GF5, and D, respectively. The cattle enrolled in this study were between 2 and 10 years old. Half of the farms housed dairy cattle in free-stall barns and half of them in tie-stall barns. In total, 266 samples were collected from these farms. This included rectal swabs and milk samples from apparently healthy dairy cattle (*n* = 210), and environmental swab samples from water trough, feed and bedding (*n* = 56).

![**Map of Nile Delta, Egypt with all locations of the dairy cattle farms from which the samples were collected (GF-Gamasa, D-Damietta)**.](fmicb-07-01020-g0001){#F1}

Bacterial strains, isolation, identification, and genomic DNA extraction
------------------------------------------------------------------------

All collected samples were enriched in buffered peptone water and cultivated on Brilliance™ ESBL agar (Oxoid, Wesel, Germany) for preliminary analysis for ESBL-producing *E. coli*. For further investigations, all suspected *E. coli* that grew on the selective medium were cultivated on tryptone yeast agar (Oxoid, Wesel, Germany). Presumptive characteristic *E. coli* isolates were identified by Gram staining and motility, and confirmed using a panel of biochemical tests (Triple Sugar Iron (TSI) agar, catalase, oxidase, H~2~S production and sugar fermentation) and API 20 E systems (bioMérieux, France; ISO, [@B19]). All confirmed isolates were subsequently re-tested using an automated microdilution technique (VITEK-2, bioMérieux, Nürtingen, Germany) that covered the following antibiotics: imipenem, meropenem, cefotaxime, ceftazidime, cefuroxime-axetil, cefuroxime, piperacillin/tazobactam, ampicillin/sulbactam, ampicillin, gentamicin, tobramycin, ciprofloxacin, moxifloxacin, tetracycline, tigecycline, co-trimoxazol, and fosfomycin (VITEK-2 test card: AST-N289). Susceptibility tests for chloramphenicol, kanamycin, streptomycin, erythromycin and colistin were not performed in this study.

Genomic DNA from clonal isolates was extracted using the DNeasy Blood & Tissue kit (Qiagen GmbH, Hilden, Germany) according to manufacturer\'s instructions. When necessary, DNA was concentrated to at least 100 ng/μl using a SpeedVac centrifuge (Eppendorf, Hamburg, Germany) at room temperature with 1400 rpm and for 30 min. Five microliters of recovered genomic DNA were used directly for biotin-labeling and subsequent hybridization.

GenoSeroTyping and antimicrobial resistance genotype
----------------------------------------------------

For all ESBL-producing *E. coli*, the serotype was determined using the *E. coli* SeroGenoTyping AS-1 kit. The antimicrobial resistance (AMR) genotype was detected by the CarbDetect AS-1 kit and all other resistance genes were detected by the *E. coli* PanType AS-2 kit (Alere Technologies GmbH, Jena, Germany). The data were automatically summarized by the "result collector," a software tool provided by Alere Technologies. An antibiotic resistance genotype was defined as a group of genes which have been described to confer resistance to a family of antibiotics (e.g., the genotype "*bla*CTX-M1/15, *bla*TEM" confers resistance to 3G cephalosporins) (**Table 2**).

Multiplex labeling, hybridization, and data analysis
----------------------------------------------------

Extracted DNA was labeled by primer extension amplification using *E. coli* SeroGenoTyping AS-1, CarbDetect AS-1 or *E. coli* PanType AS-2 kits according to manufacturer\'s instructions. The procedure for multiplex labeling, hybridization and data analysis was described in detail by Braun et al. ([@B7]). Briefly, internal labeling of the synthesized single stranded DNA resulted from the primer elongation of previously hybridized primers to the target genomic DNA, by using dUTP linked biotin as dideoxynucleotide triphosphate to be incorporated during synthesis. This procedure allowed site-specific internal labeling of the corresponding target region. The PCR protocol included 5 min of initial denaturation at 96⋅C, followed by 50 cycles with 20 s of annealing at 50⋅C, 40 s of elongation at 72⋅C, and 60 s of denaturation at 96⋅C (used device: Eppendorf Mastercycler gradient, Eppendorf, Hamburg, Germany). This reaction resulted in a multitude of specific linearly amplified, single-stranded, biotin-labeled DNA molecules for subsequent hybridization and detection using the DNA microarrays.

For hybridization procedures, the CarbDetect AS-1 and the *E. coli* PanType AS-2 kit were used according to manufacturer\'s instructions. CarbDetect ArrayStrips were placed in a thermomixer with an Alere ArrayStrip adapter (Quantifoil Instruments, Jena, Germany) and subsequently washed with 200 μl of deionized water at 50⋅C with 550 rpm for 5 min and with 100 μl hybridization buffer C1 at 50⋅C with 550 rpm for 5 min. Liquids were always completely removed using a soft plastic pipette (e.g., BRANDT, \#612-2856) to avoid any scratching of the chip surface. In a separate tube, 10 μl of previously labeled, single-stranded DNA was dissolved in 90 μl hybridization buffer C1. The hybridization was carried out at 50⋅C and 550 rpm for 1 h. After hybridization, the ArrayStrips were washed twice using 200 μl washing buffer C2 at 45⋅C for 10 min, shaking at 550 rpm. Peroxidase-streptavidin conjugate C3 was diluted 1:100 in buffer C4. A total of 100 μl of this mixture was added to each well of the ArrayStrip and subsequently incubated at 30⋅C and 550 rpm for 10 min. Thereafter, two washing steps with 200 μl C5 washing buffer were carried out at 550 rpm at 30⋅C for 5 min. The visualization was achieved by adding 100 μl of staining substrate D1 to the ArrayStrips, and signals were detected using the ArrayMate device (Alere Technologies GmbH). Finally, an automatically generated HTML-report was provided giving information on the presence or absence of antimicrobial resistance genes and the affiliation to one of the more common species.

Ethic statement
---------------

An Ethic Statement is not necessary. The isolates were obtained by noninvasive rectal swabs and no animal experiments were carried out for this study.

Results {#s3}
=======

Antimicrobial resistance genotype and phenotype
-----------------------------------------------

Rectal swabs samples (*n* = 210) yielded 98 (46.6%) cultures and environmental samples (*n* = 56) yielded 16 (28.6%) cultures of putatively ESBL-producing *E. coli*. All 114 isolates were Gram-negative, motile, catalase positive, oxidase negative and indole-producing bacteria. Additionally, all isolates caused a decrease of pH and a color change of the TSI agar indicator and gas formation in the bottom of the test tube, and were therefore assigned as *E. coli*. In total, 113 (99.1%) phenotypically 3G cephalosporin-resistant isolates harbored at least one of the ESBL genes covered by the microarray (*bla*CTX-M15, *bla*CTX-M9, *bla*TEM, *bla*SHV; Figure [2](#F2){ref-type="fig"}). The carbapenemase gene *bla*OXA-48 was detected in five isolates (3.4%) and the carbapenemase gene *bla*OXA-181 (0.8%) was detected in one isolate (Table [1](#T1){ref-type="table"}, Figure [2](#F2){ref-type="fig"}). These isolates showed a phenotypic resistance to imipenem and meropenem (Table [2](#T2){ref-type="table"}). The total number of detected resistance genes is listed in Table [1](#T1){ref-type="table"} and an overview to each isolate is given in Figure [2](#F2){ref-type="fig"}. The ESBL gene *bla*CTX-M1/15 was found in 103 isolates whereas *bla*CTX-M9 was only found in 9 isolates. Consensus sequences for *bla*TEM and *bla*SHV were found in 89 and 1 isolate, respectively. For all detected beta-lactamase genotypes, the phenotype was analyzed using the VITEK-2 instrument. The results are shown in Table [2](#T2){ref-type="table"}. The concordance for the carbapenem resistance and ESBL genotype was 100%. In one phenotypic ESBL positive isolate, only the narrow spectrum beta-lactamase (NSBL) gene *bla*OXA-1 was found. Due to this unexpected phenotype the concordance for the NSBL genotype was only 60%.

![**Overview of antimicrobial resistance pattern**. Antimicrobial resistant genes of all *E. coli* isolates obtained from swab samples (healthy dairy cattle and/or environment). Also given are the farm IDs, sample sources and sampling dates. (Abbreviations: CS, rectal swab; WT, water trough; BM, bulk milk; S, soil; FM, feed mixer; FA, feed animal; BS, boot swab; B, bedding; TMR, total mixed ration).](fmicb-07-01020-g0002){#F2}

###### 

**Antimicrobial resistance genes and their frequency in *E. coli* isolates detected by microarray**.

  **Gene family**                            **Genes**        **Accession No**.          **Description**                                                **Frequency**
  ------------------------------------------ ---------------- -------------------------- -------------------------------------------------------------- ---------------
  Carbapenemase                              *bla*OXA-48      [AY236073.2](AY236073.2)   Carbapenemase, class D carbapenem hydrolyzing beta-lactamase   5
                                             *bla*OXA-181     [JN205800.1](JN205800.1)   Carbapenemase, class D carbapenem hydrolyzing beta-lactamase   1
  ESBL (extended spectrum beta- lactamase)   *bla*CTX-M1/15   [X92506.1](X92506.1)       Class A extended-spectrum-beta-lactamase                       103
                                             *bla*CTX-M9      [AF174129.3](AF174129.3)   Class A extended-spectrum-beta-lactamase                       6
                                             *bla*TEM         Consensus                  Class A beta-lactamase                                         89
                                             *bla*SHV         Consensus                  Class A beta-lactamase                                         1
                                             *bla*MOX-CMY9    [AF381617.1](AF381617.1)   Class C beta-lactamase                                         1
  NSBL (narrow spectrum beta-lactamase)      *bla*OXA-1       [AY458016.1](AY458016.1)   Class D beta-lactamase                                         33
                                             *bla*OXA-7       [AY866525.1](AY866525.1)   Class D beta-lactamase                                         1
                                             *bla*OXA-10      [J03427.1](J03427.1)       Class D beta-lactamase                                         2
                                             *bla*CMY         [AB212086.1](AB212086.1)   Class C beta-lactamase                                         23
  Aminoglycosides                            strA             [EF090911.1](EF090911.1)   Aminoglycoside-3″-phosphotransferase (locus A)                 94
                                             strB             [EF090911.1](EF090911.1)   Aminoglycoside-6″-phosphotransferase                           94
                                             aadA4            [Z50802.3](Z50802.3)       Aminoglycoside adenyltransferase                               32
                                             aac(6′)-Ib       [AM283490.1](AM283490.1)   Aminoglycoside 6′-N-acetyltransferase                          31
                                             aac(3′)-IVa      [EU784152.1](EU784152.1)   Aminoglycoside 3′-N-acetyltransferase                          27
                                             aadA1            [EU704128.1](EU704128.1)   Aminoglycoside adenyltransferase                               25
                                             aphA             [AY260546.3](AY260546.3)   Aminoglycoside 3′-phosphotransferase                           18
                                             aadA2            [EU704128.1](EU704128.1)   Aminoglycoside adenyltransferase                               10
                                             aadB             [L06418.4](L06418.4)       Aminoglycoside 2″-O-nucleotidyltransferase                     1
  Chloramphenicol                            floR             [AF252855.1](AF252855.1)   Florfenicol export protein                                     43
                                             catB3            [AJ009818.1](AJ009818.1)   Chloramphenicol acetyltransferase (group B)                    22
                                             catA1            [V00622.1](V00622.1)       Chloramphenicol acetyltransferase (group A)                    17
                                             cmlA1            [EF113389.1](EF113389.1)   Chloramphenicol transporter                                    10
  Streptogramin A/B                          ermB             [AB089505.1](AB089505.1)   rRNA adenine N-6-methyltransferase                             4
  Macrolides                                 mphA             [AB038042.1](AB038042.1)   Macrolide 2′-phosphotransferase I                              83
                                             Mrx              [AB038042.1](AB038042.1)   Unknown (downstream to mphA)                                   82
  Fluoroquinolones                           qnrA             [AY931018.1](AY931018.1)   Quinolone or fluoroquinolone resistance protein                31
                                             qepA             [AM886293.1](AM886293.1)   Fluoroquinolone efflux pump                                    17
                                             qnrS             [AM234722.1](AM234722.1)   Quinolone or fluoroquinolone resistance protein                14
  Tetracycline                               tetA             [CP000971.1](CP000971.1)   Tetracycline resistance protein A, class A                     66
                                             tetB             [V00611.1](V00611.1)       Tetracycline resistance protein A, class B                     40
                                             tetD             [X65876.1](X65876.1)       Tetracycline resistance protein A, class D                     5
  Co-trimoxazole                             sul2             [DQ464881.1](DQ464881.1)   Dihydropteroate synthetase type 2                              96
                                             sul1             [AJ698325.1](AJ698325.1)   Dihydropteroate synthetase type 1                              72
                                             dfrA17           [AF169041.1](AF169041.1)   Dihydrofolate reductase type 17                                33
                                             dfrA14           [AJ313522.1](AJ313522.1)   Dihydrofolate reductase type 14                                20
                                             dfrA1            [AJ884723.1](AJ884723.1)   Dihydrofolate reductase type 1                                 13
                                             sul3             [AJ459418.2](AJ459418.2)   Dihydropteroate synthetase type 3                              10
                                             dfrA12           [AB154407.1](AB154407.1)   Dihydrofolate reductase type 12                                4
                                             dfrA5            [AB188269.1](AB188269.1)   Dihydrofolate reductase type 5                                 3
                                             dfrA7            [AB161450.1](AB161450.1)   Dihydrofolate reductase type 7                                 3
                                             dfrA19           [AJ310778.1](AJ310778.1)   Dihydrofolate reductase type 19                                2
                                             dfrA15           [Z83311.1](Z83311.1)       Dihydrofolate reductase type 15                                1

###### 

**In detail comparison between the microarray-based genotype and the phenotype obtained by a VITEK-2 system**.

  **AMR genotype detected by microarray[^a^](#TN1){ref-type="table-fn"}**   **Expected AMR phenotype**                                   **Frequency of genotype detected by microarray**   **Detected phenotype**                **Concordance of expected AMR phenotype (%)**                                                                                                                                                                                           
  ------------------------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------- ------------------------------------- ----------------------------------------------- --------- --------- ----- -------- --------- --------- ----- --------- ------- --------- ----- --------- ----------------------------- --------- ---------- --------- ------- --------- ---------
  *bla*OXA-48, *bla*CTX-M9, *bla*TEM                                        Carbapenem resistant                                         5                                                  MEM[^b^](#TN2){ref-type="table-fn"}   5                                               0         100       IMP   5        0         100       CTX   5         0       100       CAZ   5         0                             100       Amp        5         0       100       100
  *bla*OXA-181, *bla*CTX-M1/15, *bla*TEM, *bla*OXA-1, *bla*CMY              Carbapenem resistant                                         1                                                  MEM                                   1                                               0         100       IMP   1        0         100       CTX   1         0       100       CAZ   1         0                             100       Amp        1         0       100       100
                                                                                                                                         **6**                                                                                    **6**                                           **0**     **100**         **6**    **0**     **100**         **6**     **0**   **100**         **6**     **0**                         **100**              **6**     **0**   **100**   **100**
  *bla*CTX-M1/15, *bla*TEM                                                  3G cephalosporin resistant[^c^](#TN3){ref-type="table-fn"}   53                                                 MEM                                   0                                               53        100       IMP   0        53        100       CTX   53        0       100       CAZ   53        0                             100       Amp        53        0       100       100
  *bla*CTX-M1/15, *bla*TEM, *bla*OXA-1, *bla*CMY                            3G cephalosporin resistant                                   16                                                 MEM                                   0                                               16        100       IMP   0        16        100       CTX   16        0       100       CAZ   16        0                             100       Amp        16        0       100       100
  *bla*CTX-M1/15                                                            3G cephalosporin resistant                                   12                                                 MEM                                   0                                               12        100       IMP   0        12        100       CTX   12        0       100       CAZ   12        0                             100       Amp        12        0       100       100
  *bla*CTX-M1/15, *bla*OXA-1                                                3G cephalosporin resistant                                   10                                                 MEM                                   0                                               10        100       IMP   0        10        100       CTX   10        0       100       CAZ   10        0                             100       Amp        10        0       100       100
  *bla*CTX-M1/15, *bla*TEM, *bla*CMY                                        3G cephalosporin resistant                                   4                                                  MEM                                   0                                               4         100       IMP   0        4         100       CTX   4         0       100       CAZ   4         0                             100       Amp        4         0       100       100
  *bla*CTX-M1/15, *bla*TEM, *bla*OXA-1                                      3G cephalosporin resistant                                   3                                                  MEM                                   0                                               3         100       IMP   0        3         100       CTX   3         0       100       CAZ   3         0                             100       Amp        3         0       100       100
  *bla*CTX-M1/15, *bla*CMY                                                  3G cephalosporin resistant                                   1                                                  MEM                                   0                                               1         100       IMP   0        1         100       CTX   1         0       100       CAZ   1         0                             100       Amp        1         0       100       100
  *bla*CTX-M1/15, *bla*MOX-CMY9, *bla*TEM                                   3G cephalosporin resistant                                   1                                                  MEM                                   0                                               1         100       IMP   0        1         100       CTX   1         0       100       CAZ   1         0                             100       Amp        1         0       100       100
  *bla*CTX-M1/15, *bla*TEM, *bla*OXA-7                                      3G cephalosporin resistant                                   1                                                  MEM                                   0                                               1         100       IMP   0        1         100       CTX   1         0       100       CAZ   1         0                             100       Amp        1         0       100       100
  *bla*CTX-M1/15, *bla*TEM, *bla*SHV                                        3G cephalosporin resistant                                   1                                                  MEM                                   0                                               1         100       IMP   0        1         100       CTX   1         0       100       CAZ   1         0                             100       Amp        1         0       100       100
  *bla*CTX-M9                                                               3G cephalosporin resistant                                   1                                                  MEM                                   0                                               1         100       IMP   0        1         100       CTX   1         0       100       CAZ   1         0                             100       Amp        1         0       100       100
  *bla*TEM (consensus), *bla*CMY                                            3G cephalosporin resistant                                   1                                                  MEM                                   0                                               1         100       IMP   0        1         100       CTX   1         0       100       CAZ   1         0                             100       Amp        1         0       100       100
  *bla*TEM (consensus)                                                      3G cephalosporin resistant                                   3                                                  MEM                                   0                                               3         100       IMP   0        3         100       CTX   3         0       100       CAZ   3         0                             100       Amp        3         0       100       100
                                                                                                                                         **107**                                                                                  **0**                                           **107**   **100**         **0**    **107**   **100**         **107**   **0**   **100**         **107**   **0**                         **100**              **107**   **0**   **100**   **100**
  *bla*OXA-1                                                                NSBL                                                         1                                                  MEM                                   0                                               1         100       IMP   0        1         100       CTX   1         0       0         CAZ   1         0                             0         Amp        1         0       100       60
                                                                                                                                         **1**                                                                                    **0**                                           **1**     **100**         **0**    **1**     **100**         **1**     **0**   **0**           **1**     **0**                         **0**                **1**     **0**   **100**   **60**
  aac3lVa                                                                   Aminoglycoside resistant                                     20                                                 CN                                    20                                              0         100       TOB   20       0         100                                                                                                                                        100
  aac6lb                                                                    Aminoglycoside resistant                                     5                                                  CN                                    5                                               0         100       TOB   5        0         100                                                                                                                                        100
  aadA1                                                                     Aminoglycoside resistant                                     11                                                 CN                                    1                                               10        90        TOB   1        10        90                                                                                                                                         90
  aadA1, aac3lVa                                                            Aminoglycoside resistant                                     1                                                  CN                                    1                                               0         100       TOB   1        0         100                                                                                                                                        100
  aadA2, aadA4                                                              Aminoglycoside resistant                                     1                                                  CN                                    0                                               1         0         TOB   0        1         0                                                                                                                                          0
  aadA4                                                                     Aminoglycoside resistant                                     2                                                  CN                                    1                                               1         50        TOB   1        1         50                                                                                                                                         50
  aadA4, aac6lb                                                             Aminoglycoside resistant                                     25                                                 CN                                    22                                              3         88        TOB   25       0         100                                                                                                                                        94
  aadB, aadA1                                                               Aminoglycoside resistant                                     1                                                  CN                                    0                                               1         0         TOB   0        1         0                                                                                                                                          0
  aphA                                                                      Aminoglycoside resistant                                     6                                                  CN                                    0                                               6         100       TOB   0        6         100                                                                                                                                        100
  aphA, aadA1                                                               Aminoglycoside resistant                                     4                                                  CN                                    0                                               4         100       TOB   0        4         100                                                                                                                                        100
  aphA, aadA1, aadA2                                                        Aminoglycoside resistant                                     6                                                  CN                                    6                                               0         100       TOB   0        6         0                                                                                                                                          50
  aphA, aadA1, aadA4                                                        Aminoglycoside resistant                                     1                                                  CN                                    1                                               0         100       TOB   1        0         100                                                                                                                                        100
  aphA, aadA1, aadA4, aac6lb, aac3lVa                                       Aminoglycoside resistant                                     1                                                  CN                                    1                                               0         100       TOB   1        0         100                                                                                                                                        100
  aphA, aadA1, aadA2, aadA4                                                 Aminoglycoside resistant                                     1                                                  CN                                    1                                               0         100       TOB   1        0         100                                                                                                                                        100
  n.d.                                                                      Aminoglycoside susceptible                                   29                                                 CN                                    9                                               20        69        TOB   9        20        69                                                                                                                                         69
                                                                                                                                         **114**                                                                                  **68**                                          **46**    **73**          **65**   **49**    **67**                                                                                                                                     **77**
  tetA                                                                      Tetracycline resistant                                       55                                                 TE                                    55                                              0         100       TGC   1        54        98                                                                                                                                         99
  tetA, tetB                                                                Tetracycline resistant                                       14                                                 TE                                    14                                              0         100       TGC   0        14        100                                                                                                                                        100
  tetB                                                                      Tetracycline resistant                                       26                                                 TE                                    26                                              0         100       TGC   0        26        100                                                                                                                                        100
  tetD                                                                      Tetracycline resistant                                       6                                                  TE                                    6                                               0         100       TGC   0        6         100                                                                                                                                        100
  n.d.                                                                      Tetracycline susceptible                                     13                                                 TE                                    4                                               9         0         TGC   0        13        100                                                                                                                                        50
                                                                                                                                         **114**                                                                                  **105**                                         **9**     **80**          **1**    **113**   **100**                                                                                                                                    **90**
  qepA                                                                      Fluoroquinolone resistant                                    14                                                 CIP                                   14                                              0         100       MXF   14       0         100                                                                                                                                        100
  qepA, qnrA1                                                               Fluoroquinolone resistant                                    2                                                  CIP                                   2                                               0         100       MXF   2        0         100                                                                                                                                        100
  qnrA1                                                                     Fluoroquinolone resistant                                    31                                                 CIP                                   30                                              1         97        MXF   30       1         97                                                                                                                                         97
  qnrB                                                                      Fluoroquinolone resistant                                    1                                                  CIP                                   1                                               0         100       MXF   1        0         100                                                                                                                                        100
  qnrS                                                                      Fluoroquinolone resistant                                    10                                                 CIP                                   3                                               7         30        MXF   8        2         80                                                                                                                                         55
  qnrS, qnrA1                                                               Fluoroquinolone resistant                                    4                                                  CIP                                   2                                               2         50        MXF   3        1         75                                                                                                                                         63
  n.d.                                                                      Fluoroquinolone susceptible                                  52                                                 CIP                                   34                                              18        35        MXF   34       18        35                                                                                                                                         35
                                                                                                                                         **114**                                                                                  **86**                                          **28**    **73**          **92**   **22**    **84**                                                                                                                                     **79**
  sul1, dfrA17                                                              Co-trimoxazol resistant                                      1                                                  STX                                   1                                               0         100                                                                                                                                                                           100
  sul1, sul2, dfrA1                                                         Co-trimoxazol resistant                                      6                                                  STX                                   6                                               0         100                                                                                                                                                                           100
  sul1, sul2, dfrA17                                                        Co-trimoxazol resistant                                      22                                                 STX                                   22                                              0         100                                                                                                                                                                           100
  sul1, sul2, dfrA17, dfrA19                                                Co-trimoxazol resistant                                      1                                                  STX                                   1                                               0         100                                                                                                                                                                           100
  sul1, sul2, dfrA5                                                         Co-trimoxazol resistant                                      1                                                  STX                                   1                                               0         100                                                                                                                                                                           100
  sul1, sul2, sul3, dfrA12                                                  Co-trimoxazol resistant                                      1                                                  STX                                   1                                               0         100                                                                                                                                                                           100
  sul1, sul2, sul3, dfrA12, dfrA17                                          Co-trimoxazol resistant                                      1                                                  STX                                   1                                               0         100                                                                                                                                                                           100
  sul1, sul2, sul3, dfrA17                                                  Co-trimoxazol resistant                                      1                                                  STX                                   1                                               0         100                                                                                                                                                                           100
  sul1, sul3, dfrA5, dfrA7, dfrA14, dfrA15, dfrA17                          Co-trimoxazol resistant                                      1                                                  STX                                   1                                               0         100                                                                                                                                                                           100
  sul1, sul3, dfrA7                                                         Co-trimoxazol resistant                                      1                                                  STX                                   1                                               0         100                                                                                                                                                                           100
  sul1, sul3, dfrA7, dfrA17                                                 Co-trimoxazol resistant                                      1                                                  STX                                   1                                               0         100                                                                                                                                                                           100
  sul2, dfrA1                                                               Co-trimoxazol resistant                                      7                                                  STX                                   7                                               0         100                                                                                                                                                                           100
  sul2, dfrA12, dfrA17                                                      Co-trimoxazol resistant                                      1                                                  STX                                   1                                               0         100                                                                                                                                                                           100
  sul2, dfrA14                                                              Co-trimoxazol resistant                                      14                                                 STX                                   14                                              0         100                                                                                                                                                                           100
  sul2, dfrA14, dfrA15                                                      Co-trimoxazol resistant                                      1                                                  STX                                   1                                               0         100                                                                                                                                                                           100
  sul2, dfrA17                                                              Co-trimoxazol resistant                                      4                                                  STX                                   4                                               0         100                                                                                                                                                                           100
  sul2, dfrA5                                                               Co-trimoxazol resistant                                      2                                                  STX                                   2                                               0         100                                                                                                                                                                           100
  sul2, sul3, dfrA14                                                        Co-trimoxazol resistant                                      2                                                  STX                                   2                                               0         100                                                                                                                                                                           100
  sul3, dfrA14                                                              Co-trimoxazol resistant                                      1                                                  STX                                   1                                               0         100                                                                                                                                                                           100
  sul1                                                                      Co-trimoxazol susceptible                                    1                                                  STX                                   1                                               0         0                                                                                                                                                                             0
  sul2                                                                      Co-trimoxazol susceptible                                    3                                                  STX                                   1                                               2         66                                                                                                                                                                            66
  sul1, sul2                                                                Co-trimoxazol susceptible                                    30                                                 STX                                   29                                              1         3                                                                                                                                                                             3
  sul1, sul2, sul3                                                          Co-trimoxazol susceptible                                    1                                                  STX                                   1                                               0         0                                                                                                                                                                             0
  dfrA14                                                                    Co-trimoxazol susceptible                                    1                                                  STX                                   1                                               0         0                                                                                                                                                                             0
  dfrA17                                                                    Co-trimoxazol susceptible                                    1                                                  STX                                   1                                               0         0                                                                                                                                                                             0
  n.d.                                                                      Co-trimoxazol susceptible                                    8                                                  STX                                   0                                               8         100                                                                                                                                                                           100
                                                                                                                                         **114**                                                                                  **103**                                         **11**    **80**                                                                                                                                                                        **80**
                                                                                                                                                                                                                                                                                                                                                                                           **Overall Concordance (%)**             **83.5**                               

A genotype was defined as a group of genes which have been described to confer resistance to a family of antibiotics (e.g., the genotype "aac6, aac6ib, aadA1" confers resistance to aminoglycosides). The phenotype was detected by a VITEK-2 system.

AK amikacin, CN gentamicin, TOB tobramycin, FEP cefepime, CTX cefotaxime, CAZ ceftazidime, MEM meropenem, IMP imipenem, TE tetracycline, TGC tigecycline, STX co-trimoxazole, CIP ciprofloxacin, MXF moxifloxacin.

3G cephalosporin -- 3rd generation cephalosporin.

Nine different aminoglycoside resistance genes were detected by the *E. coli* PanType AS-1 kit (Table [1](#T1){ref-type="table"}). The combinations of these genes resulted in 14 different genotypes, whereas the most prevalent genotype was *aac(6*′*)-Ib* in combination with *aadA4* (*n* = 25). All isolates harboring this genotype were resistant to tobramycin, but three of them were susceptible to gentamicin (Table [2](#T2){ref-type="table"}). Therefore, the concordance between genotype and phenotype was 94%. Five isolates, which harbored only *aac(6*′*)-Ib*, were resistant to all tested aminoglycosides. The second most frequent genotype was *aac(3)-lVa* (*n* = 20). All isolates harboring this gene were resistant to gentamicin and tobramycin and corresponded to 100% of the expected phenotype (Table [2](#T2){ref-type="table"}). Six isolates harboring the gene *aphA* were susceptible to tobramycin and gentamicin. The detected phenotype corresponded 100% with the genotype, as the enzyme AphA does not mediate resistance against both aminoglycoside antibiotics tested (Ramirez and Tolmasky, [@B25]).

The most prevalent genotype for fluoroquinolone resistance was *qnrA1* followed by *qepA*. One isolate harboring *qnrA1* was sensitive to both quinolone antibiotics tested (97.0% concordance), but all isolates with detected *qepA* gene were resistant (100% concordance). Overall, 86 of 114 isolates were resistant to ciprofloxacin and 92 against moxifloxacin. Only in 56 ciprofloxacin resistant isolates a corresponding genotype was detected. Similar results were observed for the 92 moxifloxacin resistant isolates, where only in 68 isolates a corresponding genotype was detected. The overall concordance of the detection of genes mediating fluoroquinolone resistance with phenotypic resistance was 79.0% (Table [2](#T2){ref-type="table"}).

Resistance to co-trimoxazole is associated with *sul* and *dfrA* genes. All isolates with this gene combination were resistant to co-trimoxazole (Table [2](#T2){ref-type="table"}). From 45 isolates without this gene combination, 34 were resistant. Therefore, the concordance of genotype and phenotype was 80.0%.

Of 114 isolates, one was resistant to fosfomycin. Such resistance is caused by mutations in ubiquitous genes (e.g., *murA* or *glpT*) or the loss of entire genes (e.g., *uhpA*) rather than by acquisition of distinct resistance markers and therefore the genotypes were not included into the test panel (Takahata et al., [@B29]; Li et al., [@B20]).

In summary, the overall concordance among all genotypes to expected phenotypes was 82.6% (Table [2](#T2){ref-type="table"}).

Serotyping
----------

For all 114 ESBL-producing *E. coli* isolates, the O- and H-types were identified using the *E. coli* SeroGenotyping AS-1 kit (Figure [3](#F3){ref-type="fig"}). For 63 (55.3%) isolates, genes encoding both O and H antigens were detected and for 51 isolates (44.7%) only the gene encoding the H antigen could be detected. The most prevalent serotype was O101:H10. This serotype was found in locations D, GF1, and GF2 and isolated mainly from rectal swabs, as one isolate belonging to this group was found in a water trough. The AMR genotype for O101:H10 isolates was rather uniform (Figure [3](#F3){ref-type="fig"}). Isolates of serotype O53:H18 with the carbapenemase gene *bla*OXA-48 were only found in farm GF1 and were isolated from rectal swabs. All isolates belonging to this group were identical with regard to their phenotype and genotypes (Table [2](#T2){ref-type="table"}, Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). The serotype O8:H9 with *bla*OXA-181 was found only once in farm D from a rectal swab. For isolates where only the H-antigen H6 was found, a very similar AMR genotypes was detected. Such isolates were found in all investigated farms and sample types.

![**Overview of microarray-based serotyping**. Serotype of all *E. coli* isolates obtained from swab samples (healthy dairy cattle and/or environment). Also given are the farm IDs, sample sources and sampling dates. (Abbreviations: CS, rectal swab; WT, water trough; BM, bulk milk; S, soil; FM, feed mixer; FA, feed animal; BS, boot swab; B, bedding; TMR, total mixed ration).](fmicb-07-01020-g0003){#F3}

Discussion {#s4}
==========

In 2014, four dairy farms in northern Egypt were investigated for ESBL-producing *E. coli*. In total, 210 clinically healthy dairy cattle were sampled using rectal swabs. Additionally, 56 environmental swabs were taken from different stall objects and screened for multi-drug resistant bacteria. All swabs were pre-cultured on Brilliance™ ESBL Agar, and in 114 of 266 samples (42.8%), ESBL-producing *E. coli* were detected. To analyze the underlying molecular AMR mechanism, all 114 isolates were genotyped using the multiplex microarray technique. The most frequently detected gene which mediated resistance against 3G cephalosporins was *bla*CTX-M1/15 (90.4%). The genes *bla*CTX-M9 (5.3%) and *bla*TEM (78%), which also mediate resistance to 3G cephalosporins, were also detected. However, both were usually found in combination with *bla*CTX-M1/15. *Bla*CTX-M9 was related to resistance to 3G cephalosporins in just one isolate as well as *bla*TEM in four isolates. A comparison to data similar to data from this study is difficult due to missing reports from Egypt. Recently, two reports from Germany are known describing the prevalence of ESBL-producing bacteria in livestock of healthy animals (Schmid et al., [@B27]; Dahms et al., [@B12]). Like in the present study, in both reports the most prevalent ESBL group was CTX-M. Schmid et al. ([@B27]) collected a total of 598 samples that yielded 196 ESBL-producing *E. coli* (32.8%). The high percentage of ESBL-producing *E. coli* in healthy animals shows the high zoonotic risk for people working in close contact to animals. With this background Dahms et al. ([@B12]) investigated different farms for ESBL-producing bacteria in samples collected from livestock and also from farm workers. In total, 70.6% of the tested farms and 5.8% of the farm workers were positive for ESBL-producing bacteria. In contrast, a study from Burgundy in France in 2012 showed only a low prevalence, of about 5%, of ESBL-producing bacteria in feces samples from different farms (Hartmann et al., [@B18]).

Due to the preselection of all samples on Brilliance™ ESBL agar, carbapenem resistant isolates were also retrieved. In six isolates, carbapenemase genes were detected using the CarbDetect AS-1 kit. In five isolates from a stall on farm GF1, *bla*OXA-48 was found. These isolates were phenotypically and genotypically identical. Interestingly, another isolate was found containing *bla*OXA-181, a gene belonging to the *bla*OXA-48-like family. Both genes are also widely distributed in human pathogens that cause hospital-acquired infection (Poirel et al., [@B24]). Carbapenems are last-line antibiotics with a broad spectrum and a high efficacy, and are stable against ESBLs. As they can only be administered intravenously, carbapenems are used exclusively in the clinical environment, and are not known to be used in animal husbandry. While carbapenemase-producing *Enterobacteriaceae* (CPE) are mostly described in hospitalized humans (Nordmann et al., [@B21]; Abdallah et al., [@B2]), the current study shows conclusively that such CREs are also found in farm animals including apparently healthy dairy cattle. The detection of carbapenem resistant isolates in such an environment and the threat that such multi-drug resistance bacteria ends up in consumer food (e.g., milk or dairy products), raises serious concerns about public health. Carbapenemase-producing isolates have been detected in poultry farms (Abdallah et al., [@B1]), but there are to date no reports describing finding of these multi-drug resistant bacteria in dairy cattle farms in Egypt.

Given that the majority of samples that contained ESBL/carbapenemase-producing bacteria originated from rectal swabs, this raises the question of how the potentially contaminated feces are disposed of. Normally, dung is used as fertilizer in agriculture. Via this route, multi-drug resistant pathogens might get into the food chain, either directly through consumption of meat, or indirectly from cattle grazing on fertilized pasture. Another major problem raises up in this context, the resistance genes described in this paper are usually found on plasmids (Chanawong et al., [@B11]; Paterson and Bonomo, [@B22]; Duan et al., [@B14]; Wittum et al., [@B32]; Brolund, [@B9]; Hansen et al., [@B17]; Valentin et al., [@B30]) and such mobile elements can be easily transferred to and between environmental bacteria (Aminov, [@B4]; Berglund, [@B5]), as well as to other human pathogens (Pitout et al., [@B23]). This poses a high risk to the environment, and the human population.

Conclusion {#s5}
==========

To the best of our knowledge, this study is the first report which analyses the prevalence of ESBL-producing *E. coli* in Egyptian dairy farms based on genotyping and phenotyping data. The high percentage of ESBL-positive isolates and even of carbapenemase-producing bacteria was alarming given the relevance of 3G cephalosporins and carbapenems in modern medicine. Additionally, the isolates had a highly diverse genetic background with regard to serotype, virulence and antimicrobial resistance markers (Figures [2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). Experiments showed a high degree of concordance between genotype and phenotype.

Strict hygiene measures are mandatory to control the spread, the transmission dynamics and potential zoonotic risk factors of ESBL- and carbapenemase-producing bacteria in dairy farms.
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